This early-stage trial tests a single injection of ABI-110 gene therapy into the eye for people with wet age-related macular degeneration, including a related condition called polypoidal choroidal vasculopathy. The study involves 18 adults aged 50 to 89 and focuses on safety and …
Phase: PHASE1, PHASE2 • Sponsor: Avirmax Biopharma Inc • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC